Pharmacodynamic optimization of warfarin therapy II

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Internal Medicine

Background:

• Optimizing warfarin initiation is crucial for effective anticoagulation.
• Previous pharmacodynamic (Emax) models exist but require validation.
• Warfarin dosing presents significant interindividual variability.

Purpose of the Study:

• To assess the validity of a previously reported pharmacodynamic (Emax) model for warfarin initiation.
• To evaluate the model's performance when adjusted for age in distinct patient cohorts.
• To compare the predictive accuracy of the model against a standard induction protocol.

Main Methods:

• A pharmacodynamic (Emax) model was validated in two cohorts (Kuala Lumpur, n=31; Cambridge, n=34).
• Patients received warfarin for cardiac indications or deep vein thrombosis.
• Maintenance doses were compared with predictions from the Emax model and the Fennerty et al. protocol.

Main Results:

• The validated Emax model, incorporating age and third-day International Normalized Ratio (INR), explained two-thirds of warfarin maintenance dose variability.
• The Fennerty et al. protocol explained only one-third of the interindividual variability.
• The model demonstrated consistent predictive accuracy across both cohorts.

Conclusions:

• The validated pharmacodynamic model, presented as a nomogram, improves warfarin initiation by reducing under- and over-anticoagulation.
• It decreases the time required to establish the correct maintenance dose.
• Prospective evaluation of the nomogram is recommended for clinical implementation.